Highline Wealth Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$106K Buy
419
+72
+21% +$15.5K 0.02% 161
2026
Q1
$75.4K Buy
347
+25
+8% +$5.55K 0.02% 133
2025
Q4
$73.7K Buy
322
+32
+11% +$7.29K 0.02% 114
2025
Q3
$67.1K Buy
290
+146
+101% +$29.7K 0.02% 144
2025
Q2
$26.8K Buy
144
+17
+13% +$3.16K 0.01% 183
2025
Q1
$26.5K Buy
127
+51
+67% +$9.91K 0.01% 172
2024
Q4
$13.5K Sell
76
-5
-6% -$919 ﹤0.01% 212
2024
Q3
$16.1K Buy
81
+6
+8% +$1.12K 0.01% 205
2024
Q2
$12.8K Buy
75
+6
+9% +$994 ﹤0.01% 198
2024
Q1
$12.6K Hold
69
0.01% 208
2023
Q4
$10.7K Sell
69
-49
-42% -$7.14K 0.01% 200
2023
Q3
$17.6K Buy
118
+49
+71% +$7.19K 0.01% 156
2023
Q2
$9.3K Sell
69
-10
-13% -$1.47K 0.01% 160
2023
Q1
$12.6K Buy
79
+3
+4% +$459 0.01% 153
2022
Q4
$12.3K Hold
76
0.01% 150
2022
Q3
$10.2K Buy
+76
New +$10.9K 0.01% 140

Other funds holding ABBV

Highline Wealth Partners's ABBV Position: Q2 2026 in Review

Highline Wealth Partners increased its AbbVie (ABBV) stake by 21% in Q2 2026, buying an estimated $15.5K and bringing the position to 419 shares worth $106K. The position accounts for 0.02% of the portfolio, ranked #161.

Highline Wealth Partners first reported a position in ABBV in Q3 2022 and has held it in 16 quarters since. 1,993 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Highline Wealth Partners held 419 shares of AbbVie worth $106K as of Q2 2026.
  • Highline Wealth Partners bought 72 AbbVie shares in Q2 2026, an estimated $15.5K.
  • AbbVie made up 0.02% of Highline Wealth Partners's portfolio in Q2 2026, its #161 holding.
  • Highline Wealth Partners first reported a position in AbbVie in Q3 2022 and has held it in 16 quarters since.
  • 1,993 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.